A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling Journal Article


Authors: McArthur, H. L.; Diab, A.; Page, D. B.; Yuan, J.; Solomon, S. B.; Sacchini, V.; Comstock, C.; Durack, J. C.; Maybody, M.; Sung, J.; Ginsberg, A.; Wong, P.; Barlas, A.; Dong, Z.; Zhao, C.; Blum, B.; Patil, S.; Neville, D.; Comen, E. A.; Morris, E. A.; Kotin, A.; Brogi, E.; Wen, Y. H.; Morrow, M.; Lacouture, M. E.; Sharma, P.; Allison, J. P.; Hudis, C. A.; Wolchok, J. D.; Norton, L.
Article Title: A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling
Abstract: Purpose: To assess the safety and tolerability of preoperative cryoablation-mediated tumor antigen presentation and/or ipilimumab- mediated immune modulation in women with operable breast cancer. Experimental Design: In this pilot study, 19 women with breast cancer for whom mastectomy was planned were treated with preoperative tumor cryoablation (n = 7), single-dose ipilimumab at 10 mg/kg (n = 6), or both (n = 6). The primary outcome for this pilot study was safety/tolerability as defined as freedom from delays in pre-planned, curative-intent mastectomy. Exploratory studies of immune activationwere performed on peripheral blood and tumor. Results: Preoperative cryoablation and/or ipilimumab were safe and tolerable, with no delays in pre-planned surgery. Grade III toxicity was seen in 1 of 19 (unrelated rash after ipilimumab). Combination therapy was associated with sustained peripheral elevations in: Th1-type cytokines, activated (ICOS+) and proliferating (Ki67+) CD4+ and CD8+ T cells, and posttreatment proliferative T-effector cells relative to T-regulatory cells within tumor. Conclusions: Preoperative cryoablation and single-dose ipilimumab are safe alone or in combination with no surgical delays incurred. Potentially favorable intratumoral and systemic immunologic effects were observed with the combination, suggesting the possibility for induced and synergistic antitumor immunity with this strategy. © 2016 American Association for Cancer Research.
Journal Title: Clinical Cancer Research
Volume: 22
Issue: 23
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2016-12-01
Start Page: 5729
End Page: 5737
Language: English
DOI: 10.1158/1078-0432.ccr-16-0190
PROVIDER: scopus
PMCID: PMC5161031
PUBMED: 27566765
DOI/URL:
Notes: Article -- Export Date: 3 January 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sujata Patil
    511 Patil
  2. Monica Morrow
    772 Morrow
  3. Janice Sinae Sung
    68 Sung
  4. Mario E Lacouture
    457 Lacouture
  5. Clifford Hudis
    905 Hudis
  6. Larry Norton
    758 Norton
  7. Alan L Kotin
    15 Kotin
  8. Jedd D Wolchok
    905 Wolchok
  9. Elizabeth A Morris
    341 Morris
  10. Virgilio Sacchini
    147 Sacchini
  11. Phillip Wong
    80 Wong
  12. Majid Maybody
    98 Maybody
  13. Elizabeth Comen
    72 Comen
  14. Hannah Yong Wen
    302 Wen
  15. Stephen Solomon
    424 Solomon
  16. Afsar Barlas
    35 Barlas
  17. Edi Brogi
    516 Brogi
  18. Jianda Yuan
    105 Yuan
  19. Deirdre Neville
    11 Neville
  20. Zhiwan Dong
    8 Dong
  21. David B Page
    30 Page
  22. Brian Philip Blum
    12 Blum
  23. Jeremy Charles Durack
    116 Durack
  24. Chunjun   Zhao
    3 Zhao